An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: A randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1195-1201

  Vital, Edward M ^a,b   Dass, Shouvik ^a,b   Buch, Maya H ^a,b   Rawstron, Andrew C ^a   Emery, Paul ^a,b   Kvien, Tore K ^c  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOCYTE SUBPOPULATION; PLASMABLAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; AGED; ARTHRITIS, RHEUMATOID; CYTOLOGY; DRUG COMBINATION; FEMALE; IMMUNOLOGY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; METHOTREXATE; MIDDLE AGED; RITUXIMAB; TREATMENT OUTCOME;

EID: 84934943192     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204544     Document Type: Article

References (20)

1. Cohen SB, Greenwald M, Dougados M., et al. Efficacy and safety of rituximab in active RA patients who experienced inadequate responses to one or more TNF inhibitors. Ann Rheum Dis 2006; 65:108-9.
2. Edwards JCW, Szczepanski L, Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Eng J Med 2004; 350:2572-81.
3. Sellam J, Hendel-Chavez H, Rouanet S., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis. Arthritis Rheum 2001; 63:933-8.
4. Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72:329-36.
5. Owczarczyk K, Lal P, Abbas A.R., et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Science translational medicine 2011; 3:101ra192.
6. Sellam J, Rouanet S, Hendel-Chavez H, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011; 63:3692-701.
7. Vital EM, Dass S, Rawstron A.C., et al. Management of nonresponse to rituximab in rheumatoid arthritis predictors and outcome of re-treatment. Arthritis Rheum 2010; 62:1273-9.
8. Dass S, Rawstron AC, Vital E.M., et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58:2993-9.
9. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis efficacy depends on degree of B cell depletion. Arthritis Rheum 2011; 63:603-8.
10. Vital EM, Dass S, Rawstron A.C., et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62:1273-9.
11. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011; 63:603-8.
12. Emery P, Deodhar A, Rigby W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69:1629-35.
13. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70:39-46.
14. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49:1683-93.
15. Mariette X, Rouanet S, Sibilia J., et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 2014; 73:1508-14.
16. Moreton P, Kennedy B, Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23:2971-9.
17. Varghese AM, Cohen D, Pocock CFE, et al. NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group). ASH Annual Meeting Abstracts 2010; 116:60.
18. FDA. Public Workshop on Minimal Residual Disease. 2012 [cited May 15 2013]. http://www.gpo.gov/fdsys/pkg/FR-2012-12-26/html/2012-31044.htm
19. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909-20.
20. Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 2011; 50:2223-32.